Effectiveness of Trastuzumab As Adjuvant Therapy in Patients With Early Stage Breast Cancer: A Systematic Review and Meta-Analysis Publisher

Summary: Study shows trastuzumab improves survival in early HER2-positive breast cancer, with minimal heart risks. #BreastCancer #CancerTreatment

Davari M^{1, 2} ; Amani B³ ; Mokarian F⁴ ; Hoseini M⁵ ; Akbarzadeh A⁶ ; Khoramabadi NH⁷
Source: Medical Journal of the Islamic Republic of Iran Published:2017

Abstract

Background: Trastuzumab in combination with chemotherapy has long been established as a standard treatment for HER2-positive patients in early stage breast cancer (BC). The present study aimed at assessing the effectiveness of trastuzumab adjuvant therapy in early stage BC in overall survival (OS) and disease-free survival (DFS). Methods: A systematic review and meta-analysis was performed to evaluate the effectiveness of trastuzumab adjuvant therapy. Pub- Med, Cochrane library, Scopus, Web of Science, and Embase databases were searched for relevant RCTs from the beginning to February 2017. Quality assessment of studies was conducted using the Cochrane Risk of Bias Tool. The desired outcomes were OS and DFS. Results: A total of 1818 articles were identified first, however, only 11 studies were eligible to be included in this study. Our findings and meta-analysis results revealed that trastuzumab is effective in increasing OS (OS hazard ratio: -0.286 ± 0.049, 95%CI (-0.381, - 0.191)) and improving DFS (DFS hazard ratio: -0.419± 0.077, 95%CI (-0.569, -0.269)). The most serious but negligible side effect of trastuzumab is congestive heart failure. Conclusion: Adding trastuzumab as adjuvant therapy in early stages of BC in HER2 positive patients could increase OS and DFS of the patients effectively. © Iran University of Medical Sciences.